- Home
- KALV vs GSBC Comparison
KALV vs GSBC Comparison
Compare KALV & GSBC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KALV
- GSBC
- Stock Information
- Founded
- KALV N/A
- GSBC 1923
- Country
- KALV United States
- GSBC United States
- Employees
- KALV N/A
- GSBC N/A
- Industry
- KALV Biotechnology: Pharmaceutical Preparations
- GSBC Major Banks
- Sector
- KALV Health Care
- GSBC Finance
- Exchange
- KALV Nasdaq
- GSBC Nasdaq
- Market Cap
- KALV 551.2M
- GSBC 627.5M
- IPO Year
- KALV N/A
- GSBC N/A
- Fundamental
- Price
- KALV $13.62
- GSBC $58.16
- Analyst Decision
- KALV Strong Buy
- GSBC Hold
- Analyst Count
- KALV 8
- GSBC 2
- Target Price
- KALV $26.43
- GSBC $59.50
- AVG Volume (30 Days)
- KALV 1.2M
- GSBC 41.2K
- Earning Date
- KALV 11-10-2025
- GSBC 10-15-2025
- Dividend Yield
- KALV N/A
- GSBC 2.96%
- EPS Growth
- KALV N/A
- GSBC 18.31
- EPS
- KALV N/A
- GSBC 6.00
- Revenue
- KALV $1,426,000.00
- GSBC $228,683,000.00
- Revenue This Year
- KALV N/A
- GSBC N/A
- Revenue Next Year
- KALV $234.65
- GSBC N/A
- P/E Ratio
- KALV N/A
- GSBC $9.67
- Revenue Growth
- KALV N/A
- GSBC 7.86
- 52 Week Low
- KALV $7.30
- GSBC $47.58
- 52 Week High
- KALV $17.28
- GSBC $66.98
- Technical
- Relative Strength Index (RSI)
- KALV 70.91
- GSBC 51.91
- Support Level
- KALV $10.55
- GSBC $56.63
- Resistance Level
- KALV $13.44
- GSBC $57.63
- Average True Range (ATR)
- KALV 0.65
- GSBC 1.33
- MACD
- KALV 0.36
- GSBC 0.39
- Stochastic Oscillator
- KALV 94.79
- GSBC 93.32
About KALV KalVista Pharmaceuticals Inc.
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.
About GSBC Great Southern Bancorp Inc.
Great Southern Bancorp Inc is a bank holding company. It is principally engaged in the business of originating residential and commercial real estate loans, construction loans, commercial business loans, and consumer loans. The bank provides various services such as Business Banking, Merchant Services, Debit and Credit cards, Online Banking, Mobile Banking, VIP Banking, Overdraft Protection, and various other related services. It operates into a single segment which is Community Banking.